Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma

Completed · Phase 2

Conditions studied: Multiple Myeloma

In brief

Patients will receive Bortezomib, Dexamethasone, and Doxorubicin in 21 day cycles a total of 4 to 8 times (based on response to the treatment). Patients will also receive acetyl-L-carnitine (ALCAR) daily.

Key facts

Study ID

NCT00581919

Run by

University of Wisconsin, Madison

People needed

32

Starts

2004-02-01

Expected to finish

2013-07-01

Last updated by the study team

2019-12-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with previously treated multiple myeloma with measurable serum or urine monoclonal protein.

You may not qualify if…

• Patients with previous doxorubicin treatment totaling 220 mg/m2 or more
• LVEF less than 45%
• Patients with >grade II sensory neuropathy at baseline as assessed by the PI will be excluded
• No history of seizures as ALCAR may lower the seizure threshold
• Known HIV infection
• Current pregnancy.

Where it is running

• Mercy Health Systems — Janesville, Wisconsin, United States
• Gundersen Lutheran — La Crosse, Wisconsin, United States
• University of Wisconsin Cancer Center — Madison, Wisconsin, United States
• Regional Cancer Center — Waukesha/Oconomowoc, Wisconsin, United States
• Aspirus Wausau Hospital, Aspirus Regional Cancer Center — Wausau, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.